RLAY — Relay Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $1.21bn
- $525.81m
- $25.55m
- 71
- 11
- 33
- 31
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 82.7 | 3.03 | 1.38 | 25.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 84 | 138 | 368 | 301 | 399 |
Operating Profit | -84 | -55.8 | -365 | -299 | -373 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -75.3 | -52.4 | -364 | -291 | -342 |
Net Income After Taxes | -75.3 | -52.4 | -364 | -291 | -342 |
Net Income Before Extraordinary Items | |||||
Net Income | -75.3 | -52.4 | -364 | -291 | -342 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -75.3 | -230 | -364 | -291 | -342 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.867 | -2.56 | -2.53 | -2.59 | -2.79 |
Dividends per Share |